Endocrine Abstracts

Developments of the cancer immunology have increased the frequency of use of targeted therapies and immunomodulatory therapies. Although these treatments are effective on cancer cells, they also have toxicity on the thyroid gland. We aimed to evaluate the tyrosine kinase inhibitors(TKI) and immunotherapies-induced thyroid disorders, their relationship on disease prognosis and baseline serum thyroid stimulating hormone (TSH) levels effect on the development of thyroid dysfunction. This study was performed at a oncology center between January 2000 and December 2019. This study inclued 161 patients who were treated with immunotherapies and tyrosine kinase inhibitors. In this study, there were 161 patients whose basal thyroid function was normal. Thyroid dysfunction developed in 52 of 161(32.3%) patients. Hypothyroidism was developed in 44 of 52(84.6%) patients, and 28 of them were received L-thyroxin replacement treatment. Mean time to thyroid dysfunction development was found 14.7 weeks. By receiving operator characteristic (ROC) curve analysis, baseline serum TSH level was found as a potential predictive factor for development of hypothyroidism with a cut off value of 1.73 mIU/l, a sensitivity of 79.5% and a specifity of 56.9% and 87.3% negative predictive value(AUC:0,69, P< 0,001). Progression-free survival (PFS) time was found to be longer in patients whom occurred thyroid dysfunction during sunitinib and pazopanib treatment. Our patient population receiving immunotherapies was small and so we could not evaluated the relationship between thyroid dysfunction and PFS duration in these patient groups. More large-scale studies and longer follow-up is needed.